Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603341 · ClinicalTrials.gov registry record · NA
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
A NA study of Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- NA
- Development phase
- 1,238
- Enrollment target
- 20
- Study locations
NCT02603341 is a NA study of Breast Cancer that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1,238 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02603341, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,238 participants
- Enrollment target
- 20
- Study locations
Study Summary
A pragmatic randomized clinical trial of patients with locally advanced breast cancer randomized to either proton or photon therapy and followed longitudinally for cardiovascular morbidity and mortality, health-related quality of life, and cancer control outcomes. Quality of life is the outcome measure for the estimated primary completion date of December, 2024, www.radcomp.org.
Conditions Studied
Interventions
- RADIATION Proton
- RADIATION Photon
Study Locations (20)
Florida
- University of Miami Sylvester Cancer Center at Coral Gables - Coral Gables
- University of Miami Sylvester Cancer Center - Deerfield - Deerfield Beach
- University of Florida Health - Gainesville
- University of Florida Health Proton Therapy Institute - Jacksonville
- University of Miami Sylvester Cancer Center - Miami
- Miami Cancer Insititute - Miami
- Orlando Health - Orlando
Maryland
- University of Maryland - Baltimore
- Johns Hopkins - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
- Mass General/North Shore Cancer Center - Danvers
Michigan
- McLaren Proton Therapy - Flint
- William Beaumont - Royal Oak
Alabama
- University of Alabama - Birmingham
Arizona
- Mayo Clinic-Arizona - Phoenix
California
- UC San Diego - San Diego
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,238 participants |
| Start Date | 2016-04-06 |
| Est. Completion | 2036-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603341
The ClinicalTrials.gov registry entry for NCT02603341 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,238 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (56% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Proton is the first listed.
NCT02603341 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02603341 about?
NCT02603341 is a clinical study titled "Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial". A pragmatic randomized clinical trial of patients with locally advanced breast cancer randomized to either proton or photon therapy and followed longitudinally for cardiovascular morbidity and mortality, health-related quality of life, and cancer control outcomes. Quality of life is the outcome meas...
What is the current status of trial NCT02603341?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,238 participants. The study started on 2016-04-06. Estimated completion is 2036-11.
What conditions does trial NCT02603341 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02603341?
The interventions under investigation include: Proton (RADIATION), Photon (RADIATION).
Who is sponsoring clinical trial NCT02603341?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02603341 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.